- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03943316
Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer
Single Institution (UNM) Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer
Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.
Study Overview
Status
Conditions
Detailed Description
The purpose of this study is to collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis at the University of New Mexico Hospital or Cancer Center. Cancer cells and immune cells from the ascites fluid will be used to test novel immunotherapies for ovarian cancer treatment and to establish patient derived xenograft models to perform preclinical testing on a cancer cell population that better models the heterogeneity in patient disease
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Amy Overby
- Phone Number: 505-272-5557
- Email: Aoverby1@salud.unm.edu
Study Contact Backup
- Name: Sarah Adams, MD
- Phone Number: (505) 925-0461
- Email: SAdams@salud.unm.edu
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- Recruiting
- University of New Mexico Cancer Center
-
Contact:
- Amy Overby
- Phone Number: 505-272-5557
- Email: Aoverby1@salud.unm.edu
-
Contact:
- Sharareh Sazesh, MS
- Email: ssazesh@salud.unm.edu
-
Principal Investigator:
- Sarah Adams, MD
-
Sub-Investigator:
- Carolyn Muller, MD
-
Sub-Investigator:
- Bridget Wilson, PhD
-
Sub-Investigator:
- Laurie Hudson, PhD
-
Sub-Investigator:
- Angela Wandinger-Ness, PhD
-
Sub-Investigator:
- Helen Hathaway, PhD
-
Sub-Investigator:
- Eric Prossnitz, PhD
-
Sub-Investigator:
- Mara Steinkamp, PhD
-
Sub-Investigator:
- Sabrina Samudio-Ruiz, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study; All participants will be eighteen years old or older; Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection.
Description
Inclusion Criteria:
-
All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study
-
All participants will be eighteen years old or older
-
Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection.
-
Ability to understand and the willingness to sign a written informed consent document.
-
Pathologic confirmation of a diagnosis of epithelial adenocarcinoma of the ovary, fallopian tube, or primary peritoneal cancer (serous, mucinous, clear cell, endometrioid, undifferentiated, mixed, transitional cell)
-
Women of childbearing potential must have a negative qualitative serum pregnancy test ≤ 2 weeks prior to study entry.
-
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
Exclusion Criteria:
- We do not intend to include participants if they are unable to provide informed consent for this study themselves (e.g. mentally ill patients who require health care proxies to consent for any medical intervention), or vulnerable populations such as prisoners.
- Minors under age eighteen.
- Pregnant women.
- Final pathologic diagnosis that does not confirm invasive epithelial ovarian, tubal, or primary peritoneal cancer
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Collect ascites fluid obtained from ovarian cancer patients during cytoreductive surgery or paracentesis
Time Frame: 5 years
|
To elucidate the conditions of the tumor environment that contribute to cancer dissemination in the peritoneal cavity through ex vivo evaluation of malignant ascites collected from women with ovarian, tubal, or primary peritoneal cancer. |
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To correlate specific features of peritoneal cell populations or soluble factors with patient outcome.
Time Frame: 5 years
|
To correlate specific features of peritoneal cell populations or soluble factors with patient outcome. |
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sarah Adams, MD, UNM Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Pathologic Processes
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Pathological Conditions, Signs and Symptoms
- Ovarian Neoplasms
- Ascites
Other Study ID Numbers
- INST UNM 1509
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.